Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU2 | Q9Y3R4 | 8/20 | 0.55 |
| ▸ | NEU3 | Q9UQ49 | 7/20 | 0.55 |
| ▸ | NEU4 | Q8WWR8 | 6/20 | 0.55 |
| ▸ | NEU1 | Q99519 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677345 | 1.00 | NEU2 (0.55) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL126534 | 1.00 | NEU2 (0.55) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL23366169 | 0.93 | NEU2 (0.46) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL14050239 | 0.91 | NEU2 (0.45) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL7829023 | 0.89 | NEU2 (0.43) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL6328640 | 0.89 | NEU2 (0.43) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL7829019 | 0.89 | NEU2 (0.43) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL26839253 | 0.82 | NEU2 (0.36) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL3682976 | 0.81 | NEU2 (0.33) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL21240052 | 0.81 | NEU2 (0.33) | NEU2NEU3NEU4NEU1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795301-B2 | Dimeric compounds and their use as anti-viral agents | BIOTA SCIENTIFIC MANAGEMENT PTY, LTD. (AU) | 2010-09-14 | — | — | US | disclosed |
| US-7504434-B2 | Dimeric compounds and their use as anti-viral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2009-03-17 | — | — | US | disclosed |
| EP-1423385-B1 | INTERMEDIATES FOR PREPARING NEURAMINIDASE INHIBITOR CONJUGATES | BIOTA SCIENT MANAGEMENT (AU) | 2008-07-02 | — | — | EP | disclosed |
| EP-1451184-B1 | DIMERIC COMPOUNDS AND THEIR USE AS ANTI-VIRAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2008-06-11 | — | — | EP | disclosed |
| US-20070225361-A1 | DIMERIC COMPOUNDS AND THEIR USE AS ANTI-VIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. | 2007-09-27 | — | — | US | disclosed |
| US-20070225359-A1 | DIMERIC COMPOUNDS AND THEIR USE AS ANTI-VIRAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. | 2007-09-27 | — | — | US | disclosed |
| US-7230114-B2 | Intermediates for preparing neuraminidase inhibitor conjugates | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-06-12 | — | — | US | disclosed |
| US-7230028-B2 | Dimeric compounds and their use as anti-viral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2007-06-12 | — | — | US | disclosed |
| US-7214707-B2 | Dimeric compounds and their use as anti-viral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2007-05-08 | — | — | US | disclosed |
| US-20050085413-A1 | Dimeric pharmaceutical compounds and their use | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2005-04-21 | — | — | US | disclosed |
| US-20050043399-A1 | Dimeric compounds and their use as anti-viral agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225359-A1 | DIMERIC COMPOUNDS AND THEIR USE AS ANTI-VIRAL AGENTS | SARS1, EIF2AK2, ZC3HAV1 | NEU2 680/4885NEU3 917/4885NEU4 1355/4885 |
| US-20050043399-A1 | Dimeric compounds and their use as anti-viral agents | SARS1, EIF2AK2, ZC3HAV1 | NEU2 680/4885NEU3 917/4885NEU4 1355/4885 |
| US-20050085413-A1 | Dimeric pharmaceutical compounds and their use | FPR1, F12, XDH | NEU2 1548/4885NEU3 2516/4885NEU4 3342/4885 |
| US-20070225361-A1 | DIMERIC COMPOUNDS AND THEIR USE AS ANTI-VIRAL AGENTS | EIF2AK2, IRF3, SARS1 | NEU2 566/4885NEU3 913/4885NEU4 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.